2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)

Bibliographic Details
Main Authors:	Yokota S, Imagawa T, Miyamae T, Kasai K, Mori M, Nishimoto N, Kishimoto T
Format:	Article
Language:	English
Published:	BMC 2008-09-01
Series:	Pediatric Rheumatology Online Journal

Similar Items

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
by: Yokota Shumpei, et al.
Published: (2011-09-01)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
by: De Benedetti Fabrizio, et al.
Published: (2012-07-01)

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
by: Murakami M, et al.
Published: (2012-07-01)

Thalidomide: efficacy and side effects in juvenile idiopathic arthritis (JIA)
by: Alpigiani MG, et al.
Published: (2008-09-01)

TOCILIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH SEVERE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: E.I. Alexeeva, et al.
Published: (2011-05-01)

TOCILIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH SEVERE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: E.I. Alexeeva, et al.
Published: (2011-01-01)

Talus Arthritis Pattern in Juvenile Idiopathic Arthritis (JIA)
by: Mohammad Alkhreisat MD, et al.
Published: (2019-10-01)

THE CLINICAL AND PARACLINICAL EFFICACY OF TOCILIZUMAB IN JUVENILE IDIOPATHIC ARTHRITIS
by: Ninel REVENCO, et al.
Published: (2021-06-01)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
by: Hofer M, et al.
Published: (2011-09-01)

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
by: Sleptsova T, et al.
Published: (2011-09-01)

Mandibular condyle destruction in juvenile idiopathic arthritis (JIA)
by: Zak M, et al.
Published: (2008-09-01)

The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
by: Joly J, et al.
Published: (2011-09-01)

Correlation between clinical indices and findings of joint ultrasonography in juvenile idiopathic arthritis with adalimumab therapy
by: Mori Masaaki, et al.
Published: (2011-09-01)

Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA) therapy
by: Alpigiani MG, et al.
Published: (2008-09-01)

Infliximab to treat chronic uveitis in juvenile idiopathic arthritis (JIA)
by: Bracaglia C, et al.
Published: (2008-09-01)

Juvenile idiopathic arthritis (JIA): can an integrated medicine be possible?
by: Carlomagno R, et al.
Published: (2011-09-01)

Rituximab in ANA positive polyarticular juvenile idiopathic arthritis (JIA) with uveitis
by: Baildam EM, et al.
Published: (2008-09-01)

Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA)
by: Verazza S, et al.
Published: (2008-09-01)

Replication of the association of the <it>COG6</it> gene with juvenile idiopathic arthritis (JIA)
by: Worthington J, et al.
Published: (2011-09-01)

Rapid desensitisation to tocilizumab in systemic idiopathic juvenile arthritis
by: Rosalaura Villarreal González, et al.
Published: (2021-03-01)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
by: Espada G, et al.
Published: (2011-09-01)

14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
by: Hunter PJ, et al.
Published: (2008-09-01)

How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
by: Nageswaran Savithri, et al.
Published: (2008-06-01)

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
by: Dehoorne J, et al.
Published: (2011-09-01)

Psychological characteristics of the patients with juvenile idiopathic arthritis (JIA) of various age groups
by: Stepanenko NY
Published: (2011-09-01)

The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
by: Saskia Lawson-Tovey, et al.
Published: (2023-07-01)

EFFICACY AND SAFETY OF TOCILIZUMAB IN CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS IN CLINICAL PRACTICE
by: M. I. Kaleda, et al.
Published: (2015-04-01)

Efficacy of a second TNF blocker, when the first one failed, in patients with juvenile idiopathic arthritis (JIA)
by: Salmaso A, et al.
Published: (2008-09-01)

Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF
by: Pontikaki I, et al.
Published: (2008-09-01)

Development and initial validation of the parent acceptable symptom state in juvenile idiopathic arthritis (JIA)
by: Filocamo G, et al.
Published: (2008-09-01)

Analysis of ceiling effect and score distribution of outcome measures in juvenile idiopathic arthritis (JIA)
by: Lattanzi B, et al.
Published: (2008-09-01)

Juvenile idiopathic arthritis (JIA) in two tertiary centres in the Western Cape, South Africa
by: Pope Chris, et al.
Published: (2011-09-01)

An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
by: Bullement A, et al.
Published: (2021-09-01)

German evidence- and consensus-based guidelines 2011 for the treatment of juvenile idiopathic arthritis (JIA)
by: Dueckers Gregor, et al.
Published: (2012-07-01)

Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
by: Kumar Sharath, et al.
Published: (2012-11-01)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
by: Claudia Iannone, et al.
Published: (2023-02-01)

THE PHENOMENON OF NEUTROPENIA DURING TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
by: M. I. Kaleda, et al.
Published: (2018-01-01)

Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis
by: Tingyan He, et al.
Published: (2023-06-01)

Tocilizumab for juvenile idiopathic arthritis: a single-center case series
by: Fatma Yazılıtaş, et al.
Published: (2020-03-01)

Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Children with Severe Systemic Juvenile Idiopathic Arthritis: 12-month Follow-up
by: A. A. Baranov, et al.
Published: (2013-03-01)